DEF: Tilray Brands Seeks Board Declassification, Executive Pay Vote

Tilray Brands, Inc. announces its 2025 Annual Meeting of Stockholders to vote on director election, auditor ratification, executive compensation, and a significant governance proposal to declassify its Board.

Summary

• The Annual Meeting of Stockholders is scheduled for Tuesday, November 18, 2025, at 11:00 a.m. EST, and will be held in a virtual format.
• Shareholders will vote on the election of John Herhalt as a Class I director nominee, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending May 31, 2026, and a non-binding advisory resolution on named executive officer compensation.
• A key proposal, the 'Governance Proposal,' seeks to amend the company's charter to declassify the Board, providing for the annual election of all directors, and to eliminate the 'for cause' requirement for director removal, allowing removal with or without cause by a majority vote. This proposal previously failed to pass in 2023 and 2024.
• For Fiscal Year 2025, the company did not fully achieve its financial performance targets, including revenues of $950 million (actual $821 million), Adjusted EBITDA of $62 million (actual $55 million), and positive free cash flow (actual negative).
• As a result of not meeting financial targets, no annual incentive payments ($0) were awarded to executive officers for Fiscal Year 2025.
• The Board approved retention bonus payments to Named Executive Officers (NEOs) in August 2024, requiring continued employment through August 31, 2025, with pro-rated repayment if employment terminates early without good reason or for cause.
• The CEO's total compensation for Fiscal Year 2025 was $10,295,612, resulting in a CEO Pay Ratio of 266 to 1 compared to the median employee's total compensation of $38,658.
• The Board of Directors unanimously recommends voting FOR all proposals, including the election of John Herhalt, auditor ratification, executive compensation, and the Governance Proposal.

Sentiment

Score: 4

Explanation: While the company highlights several operational achievements and strategic integrations, the failure to meet key financial targets (revenue, Adjusted EBITDA, free cash flow) for Fiscal Year 2025, leading to zero annual executive bonuses, indicates underperformance in core financial metrics. The repeated failure of the Governance Proposal to pass also suggests ongoing shareholder friction or lack of consensus on significant governance changes.

Positives

• Strengthened the company's balance sheet by significantly reducing outstanding bank debt and the principal balance of convertible notes.
• Drove meaningful revenue growth and improved operating performance in key business units.
• Developed and launched a range of product innovations and improved production efficiencies.
• Implemented strategic initiatives to expand production and sales of cannabis in Europe and other geographic regions.
• Successfully resolved several material, legacy litigation claims through dismissal orders and settlements at less than 10% of potential exposure.
• Completed and effectively integrated the strategic acquisition of craft beer brands from Molson Coors, achieving identified cost savings.
• The Board is committed to fostering a board of directors with diverse perspectives, backgrounds, and experiences, with 14.3% female directors.
• Maintains a Code of Conduct and robust corporate governance practices, including independent committees and risk oversight.

Negatives

• Did not fully achieve all financial metrics required for annual incentive awards in Fiscal Year 2025.
• Actual revenues for Fiscal Year 2025 were $821 million, falling short of the $950 million target.
• Actual Adjusted EBITDA for Fiscal Year 2025 was $55 million, below the $62 million target.
• The company reported negative free cash flow for Fiscal Year 2025, missing the target of positive free cash flow.
• No annual incentive payments were awarded to executive officers for Fiscal Year 2025 due to the failure to fully achieve financial performance targets.
• The Governance Proposal to declassify the Board and allow director removal without cause has failed to receive the requisite 66 2/3% stockholder approval in both 2023 and 2024.
• The CEO Pay Ratio for Fiscal Year 2025 was 266 to 1, with the CEO's total compensation at $10,295,612 and the median employee's at $38,658.

Risks

• Actual results may differ materially from forward-looking statements due to factors detailed in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under 'Risk Factors and Safe Harbor for Forward-Looking Statements'.
• The Audit Committee is responsible for considering and discussing major financial risk exposures and overseeing emerging areas of risk, such as environmental risk exposures.
• The Compensation Committee assesses and monitors whether any compensation policies and programs have the potential to encourage excessive risk-taking.
• The Board and Audit Committee receive periodic reports on primary cybersecurity risks facing the company and mitigation measures.

Future Outlook

The company's compensation program is tied to key strategic initiatives, including increasing revenues and adjusted EBITDA, diversifying the revenue base with accretive and strategic acquisitions, strengthening the balance sheet through ongoing debt reductions, and advancing product innovation and development. The Board will continue to evaluate the appropriateness of its peer group for compensation annually and make necessary changes for Fiscal Year 2026 as the cannabis industry and business evolve. The Compensation Committee will consider the results of the annual say-on-pay vote and specific shareholder input for future executive compensation arrangements.

Management Comments

• "We are grateful for your continued support and will work everyday to take full advantage of all opportunities to enhance long-term value." Irwin D. Simon, Chairman, President, and Chief Executive Officer.
• "We believe that a virtual meeting will provide expanded stockholder access and participation, as well as improved communications."
• "The Board believes that combining the positions of Chief Executive Officer and Board Chair helps to ensure that the Board and management act with a common purpose."
• "The Board believes that it is best served by having a separate independent director (currently Ms. Persofsky) serve as the Company's Vice Chair to facilitate strong communication and coordination between management and the independent members of the Board."
• "The Board values the input of the stockholders who engaged with us on these important matters, and believes that the changes enhance stockholder rights, provide increased accountability of the Company and our Board to our stockholders, and give us an opportunity to further demonstrate our values and commitment to advancing diversity, equity and inclusion."
• "The Company continues to maintain that the compensation decisions on which the 2023 say-on-pay vote was based were necessary to retain our talented executive team and reward them for their outstanding efforts."

Industry Context

Tilray Brands operates in multiple industries including medical and adult-use cannabis, wellness foods, beverages (craft beer, spirits, cannabis drinks). It positions itself as the #1 medical and adult-use cannabis company in Canada, a leader in medical cannabis across Europe, and the 5th largest craft brewer in the United States. Its compensation peer group includes companies from cannabis, biotech/pharmaceuticals, and consumer-packaged goods/alcohol industries, reflecting its diversified business model and international operations. The company's strategic initiatives focus on revenue growth, adjusted EBITDA, diversification through acquisitions, debt reduction, and product innovation, which are common themes across competitive, growing industries. The mention of expanding cannabis sales in Europe indicates a focus on international market penetration, a key trend in the evolving global cannabis sector.

Comparison to Industry Standards

• The executive compensation program aims to be competitive with compensation offered to executives in comparable positions in cannabis, biotech/pharmaceuticals, and consumer-packaged goods companies of similar size and operating in similar geographies.
• The Compensation Committee utilizes an 18-company peer group for benchmarking executive compensation, including: Cannabis companies (Canopy Growth Corporation, Curaleaf Holdings, Inc., Cresco Labs, Inc., Green Thumb Industries, Inc., GW Pharmaceuticals plc, Trulieve Cannabis Corp.); Biotechnology/Pharmaceutical/Technology companies (Catalent, Inc., DocuSign, Inc., Etsy, Inc., Incyte Corporation, Neurocrine Biosciences, Inc., Unity Software Inc.); and Consumer Packaged Goods/Alcohol companies (Beyond Meat, Constellation Brands, Inc., Monster Beverage, National Beverage, The Boston Beer Company, Inc., The Simply Good Food Co.).
• The company's total shareholder return (TSR) is compared against the Horizons Marijuana Life Sciences Index as its peer group index for performance graph purposes.

Management Changes

Corporate Governance

Legal Proceedings

• Successfully resolved several material, legacy litigation claims through dismissal orders and settlements at less than 10% of potential exposure.

Related Party Transactions

• No transactions for the fiscal year ended May 31, 2025, in which Tilray was a participant, where the amount involved exceeded $120,000 and any directors, executive officers, or greater than 5% stockholders (or their immediate family/affiliates) had a direct or indirect material interest.
• A formal written policy adopted in July 2018 requires prior Audit Committee consent for related-party transactions exceeding $120,000.

Stakeholder Impact

• Shareholders are directly impacted by voting on director election, auditor ratification, executive compensation, and the significant Governance Proposal (Board declassification, director removal). The failure to meet financial targets and the CEO pay ratio may be concerns, while efforts to strengthen the balance sheet, resolve litigation, and integrate acquisitions are positive for long-term value.
• Executive Officers (NEOs) had no annual incentive payments for FY2025 due to missed financial targets, but retention awards were granted to ensure continued incentivization. Equity awards are a significant component of their compensation, aligning their interests with long-term shareholder value.
• Customers may benefit from product innovations and improved production efficiencies, and the expansion of cannabis sales in Europe.
• Creditors are positively impacted by the strengthening of the balance sheet through significant reductions in bank debt and convertible notes.

Next Steps

• The Annual Meeting of Stockholders will be held on November 18, 2025, to vote on the proposed matters.
• If the Governance Proposal is approved, the company will file a Certificate of Amendment with the Secretary of State of Delaware promptly after the Annual Meeting.
• If the Governance Proposal is approved, all current directors will stand for re-election at the 2026 annual meeting for one-year terms.
• Final voting results will be reported on a Current Report on Form 8-K filed with the SEC within four business days of the Annual Meeting.
• The Compensation Committee will continue to evaluate the appropriateness of its peer group annually and make necessary changes for Fiscal Year 2026.
• The Compensation Committee will consider the results of the annual say-on-pay vote and specific shareholder input in determining 2026 and future executive compensation programs.
• The next say-on-frequency vote for executive compensation will be held at the 2027 Annual Meeting.
• Stockholder proposals and director nominations for the 2026 Annual Meeting must be received by May 30, 2026 (under Rule 14a-8) or between May 27, 2026, and June 26, 2026 (outside Rule 14a-8).
• The Compensation Committee will determine the earned percentage and payout of the 2024 EBITDA PSU Awards in July 2026, based on satisfaction of cumulative 3-year performance goals.

Key Dates

Recommendation

The company demonstrated strong operational execution in Fiscal Year 2025, including significant debt reduction, successful acquisition integration, product innovation, and expansion into European cannabis markets. These achievements suggest a management team capable of strategic execution. However, the failure to meet key financial targets (revenue, Adjusted EBITDA, and positive free cash flow) for the fiscal year, leading to zero annual executive bonuses, indicates underperformance in core financial metrics. The repeated failure of the Governance Proposal to declassify the Board also highlights potential ongoing shareholder governance concerns. Given the mixed financial results against operational strengths, a 'hold' recommendation is appropriate, suggesting investors monitor the company's ability to translate operational improvements into consistent financial outperformance and the outcome of the governance vote.

Keywords

Tilray Brands, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Board Declassification, Annual Meeting, Financial Performance, Cannabis Industry, Consumer Packaged Goods, Brewery, Spirits, Risk Management, Shareholder Vote, PricewaterhouseCoopers LLP, John Herhalt, Irwin D. Simon, Adjusted EBITDA, Revenue